IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells

Cancer Research

Volumn 75, Issue 8, 2015, Pages 1635-1644

  Sun, Zhaojun ^a   Fourcade, Julien ^a   Pagliano, Ornella ^a   Chauvin, Joe Marc ^a   Sander, Cindy ^a   Kirkwood, John M ^a   Zarour, Hassane M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; ANTIBODY; IL10 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; PDCD1 PROTEIN, HUMAN;

ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHOCYTE FUNCTION; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL CULTURE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; SKIN TUMOR; TUMOR ESCAPE;

ANTIBODIES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, INTERLEUKIN-10; SKIN NEOPLASMS; TUMOR ESCAPE;

EID: 84942890083     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3016     Document Type: Article

References (43)

1. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T-cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
2. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004; 78: 5535-45.
3. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12: 492-9.
4. Barber DL, Wherry EJ, Masopust D, Zhu B., Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-7.
5. + T-cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10: 29-37.
6. + T-cell expansion in melanoma patients. J Immunol 2009; 182: 5240-9.
7. + T-cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175-86.
8. Fourcade J, Sun Z, Pagliano O., Guillaume P, Luescher IF, Sander C, et al CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012; 72: 887-96.
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
10. Hamid O, Robert C, Daud A., Hodi FS, Hwu WJ, Kefford R, et al Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-44.
11. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
12. Ouyang W, Rutz S, Crellin N.K., Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011; 29: 71-109.
13. Sato T, McCue P, Masuoka K., Salwen S, Lattime EC, Mastrangelo M.J., et al. Interleukin 10 production by human melanoma. Clin Cancer Res 1996; 2: 1383-90.
14. Chen Q, Daniel V, Maher D.W., Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994; 56: 755-60.
15. Dummer W, Bastian BC, Ernst N, Schanzle C., Schwaaf A, Brocker EB. Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996; 66:607-10.
16. Castro AG, Neighbors M, Hurst S.D., Zonin F., Silva RA, Murphy E, et al. Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopoly-saccharide. J Exp Med 2000; 192: 1529-34.
17. Vicari AP, Chiodoni C, Vaure C., Ait-Yahia S, Dercamp C, Matsos F., et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002; 196: 541-9.
18. Sharma S, Stolina M, Lin Y., Gardner B, Miller PW, Kronenberg M, et al T cell-derived IL-10 promotes lung cancer growth by suppressing both T-cell and APC function. J Immunol 1999; 163: 5020-8.
19. Hagenbaugh A, Sharma S, Dubinett S.M., Wei SH, Aranda R, Cheroutre H, et al Altered immune responses in interleukin 10 transgenic mice. J Exp Med 1997; 185: 2101-10.
20. Berman RM, Suzuki T, Tahara H., Robbins PD, Narula SK, Lotze MT. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol 1996; 157: 231-8.
21. Giovarelli M, Musiani P, Modesti A., Dellabona P, Casorati G, Allione A., et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 1995; 155: 3112-23.
22. Richter G, Kruger-Krasagakes S, Hein G., Huls C, Schmitt E, Diamantstein T., et al. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res 1993; 53: 4134-7.
23. Fujii S, Shimizu K, Shimizu T., Lotze MT. Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood 2001; 98: 2143-51.
24. Tanikawa T, Wilke CM, Kryczek I, Chen G.Y., Kao J., Nunez G, et al. Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res 2012; 72: 420-9.
25. Emmerich J, Mumm JB, Chan I.H., LaFace D., Truong H, McClanahan T, et al IL-10 directly activates and expands tumor-residentCD8(+)Tcells without de novo infiltration from secondary lymphoid organs. Cancer Res 2012; 72: 3570-81.
26. Mumm JB, Emmerich J, Zhang X., Chan I, Wu L, Mauze S., et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell 2011; 20: 781-96.
27. Brooks DG, Ha SJ, Elsaesser H, Sharpe A.H., Freeman GJ, Oldstone MB. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci U S A 2008; 105: 20428-33.
28. + T-cell activation during HIV infection. Nat Med 2010; 16: 452-9.
29. Stordeur P, Poulin LF, Craciun L, Zhou L., Schandene L, de Lavareille A, et al. Cytokine mRNA quantification by real-time PCR (vol 259, pg 55, 2002). J Immunol Methods 2002; 262: 229.
30. Liu Y, Wei SH, Ho A.S., de Waal Malefyt R, Moore KW. Expression cloning and characterization of a human IL-10 receptor. J Immunol 1994; 152: 1821-9.
31. Fortis C, Foppoli M, Gianotti L., Galli L, Citterio G, Consogno G., et al. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 1996; 104: 1-5.
32. Nemunaitis J, Fong T, Shabe P., Martineau D, Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 2001; 19: 239-47.
33. Jin HT, Anderson AC, Tan W.G., West EE, Ha SJ, Araki K, et al Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 2010; 107: 14733-8.
34. Day CL, Kaufmann DE, Kiepiela P, Brown J.A., Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-4.
35. + T cells leads to reversible immune dysfunction. Nat Med 2006; 12: 1198-202.
36. Sakuishi K, Apetoh L, Sullivan J.M., Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways toreverse T-cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-94.
37. + T cells. J Exp Med 1996; 184: 19-29.
38. O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonistsin human disease. Immunol Rev 2008; 223: 114-31.
39. + T cells. J Immunol 1998; 160: 3188-93.
40. Clerici M, Wynn TA, Berzofsky J.A., Blatt SP, Hendrix CW, Sher A, et al Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994; 93:768-75.
41. Torisu-Itakura H., Lee JH, Huynh Y, Ye X., Essner R, Morton DL. Monocyte-derived IL-10 expression predicts prognosis of stage IV melanoma patients. J Immunother 2007; 30: 831-8.
42. + T-cell exhaustion during chronic viral infection. Immunity 2007; 27: 670-84.
43. Ejrnaes M, Filippi CM, Martinic M.M., Ling EM, Togher LM, Crotty S, et al Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006; 203: 2461-72.